Arcutis Biotherapeutics (ARQT)
(Delayed Data from NSDQ)
$10.14 USD
-0.26 (-2.50%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $10.14 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Arcutis Biotherapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -262.14 | -311.46 | -206.36 | -135.68 | -42.00 |
Depreciation/Amortization & Depletion | -5.47 | -1.32 | 3.91 | 0.19 | -0.16 |
Net Change from Assets/Liabilities | -23.50 | -10.18 | 3.62 | 14.13 | -1.51 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 44.05 | 65.24 | 24.20 | 8.32 | 0.82 |
Net Cash From Operating Activities | -247.06 | -257.72 | -174.63 | -113.03 | -42.84 |
Property & Equipment | -0.43 | -15.78 | -1.00 | -0.32 | -0.30 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 180.66 | -63.92 | -74.96 | -181.50 | -26.03 |
Other Investing Activities | 0.00 | -7.50 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 180.23 | -87.20 | -75.95 | -181.82 | -26.33 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 98.19 | 164.53 | 209.60 | 298.15 | 94.50 |
Issuance (Repayment) of Debt | 0.00 | 125.00 | 73.99 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 3.14 | 12.27 | -1.64 | 0.00 | -1.40 |
Net Cash from Financing Activities | 101.32 | 301.80 | 281.95 | 298.15 | 93.10 |
Effect of Exchange Rate Changes | -0.05 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 34.45 | -43.12 | 31.37 | 3.29 | 23.94 |
Cash at Beginning of Period | 54.88 | 97.99 | 66.62 | 63.34 | 39.39 |
Cash at End of Period | 89.32 | 54.88 | 97.99 | 66.62 | 63.34 |
Diluted Net EPS | -3.78 | -5.66 | -4.18 | -3.80 | -22.78 |
Fiscal Year End for Arcutis Biotherapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -87.71 | -35.38 | -262.14 | -195.86 | -151.09 |
Depreciation/Amortization & Depletion | -3.40 | -1.37 | -5.47 | -4.38 | -3.24 |
Net Change from Assets/Liabilities | -9.71 | -5.44 | -23.50 | -23.91 | -14.73 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 24.11 | 10.59 | 44.05 | 33.34 | 22.23 |
Net Cash From Operating Activities | -76.72 | -31.60 | -247.06 | -190.81 | -146.83 |
Property & Equipment | 0.00 | 0.00 | -0.43 | -0.42 | -0.36 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -90.83 | -28.70 | 180.66 | 242.84 | 197.23 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -90.83 | -28.70 | 180.23 | 242.42 | 196.87 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 163.22 | 161.76 | 98.19 | 2.03 | 1.17 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 3.14 | 0.00 | 0.00 |
Net Cash from Financing Activities | 163.22 | 161.76 | 101.32 | 2.03 | 1.17 |
Effect of Exchange Rate Changes | -0.10 | -0.07 | -0.05 | -0.12 | -0.04 |
Net Change In Cash & Equivalents | -4.44 | 101.39 | 34.45 | 53.52 | 51.16 |
Cash at Beginning of Period | 89.32 | 89.32 | 54.88 | 54.88 | 54.88 |
Cash at End of Period | 84.89 | 190.71 | 89.32 | 108.40 | 106.04 |
Diluted Net EPS | -0.42 | -0.32 | -0.58 | -0.73 | -1.16 |